Biora Therapeutics, Inc. Net Cash Provided by (Used in) Operating Activities, Continuing Operations
Biora Therapeutics, Inc. reported Net Cash Provided by (Used in) Operating Activities, Continuing Operations of -$48.50 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations · last filed 2024-04-01
- Biora Therapeutics, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2023-12-31 was -$13.74M.
- Biora Therapeutics, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2023-09-30 was -$11.03M.
- Biora Therapeutics, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2023-06-30 was -$11.62M.
- Biora Therapeutics, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2023-03-31 was -$12.10M.
- Biora Therapeutics, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2023 was -$48.50M.
- Biora Therapeutics, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2022 was -$66.17M.
- Biora Therapeutics, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2021 was -$140.33M.
- Biora Therapeutics, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2020 was -$92.96M.
| Period end | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$13.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$24.78M derived: sum of 2 quarters · filed 2024-04-01 | -$36.40M derived: sum of 3 quarters · filed 2024-04-01 | -$48.50M 10-K · filed 2024-04-01 |
| 2023-09-30 | -$11.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$22.66M derived: sum of 2 quarters · filed 2023-11-13 | -$34.75M 10-Q · filed 2023-11-13 | -$45.62M derived: sum of 4 quarters · filed 2024-04-01 |
| 2023-06-30 | -$11.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$23.72M 10-Q · filed 2023-08-14 | -$34.58M derived: sum of 3 quarters · filed 2024-04-01 | -$44.48M derived: sum of 4 quarters · filed 2024-04-01 |
| 2023-03-31 | -$12.10M 10-Q · filed 2023-05-15 | -$22.96M derived: sum of 2 quarters · filed 2024-04-01 | -$32.86M derived: sum of 3 quarters · filed 2024-04-01 | -$52.98M derived: sum of 4 quarters · filed 2024-04-01 |
| 2022-12-31 | -$10.86M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$20.76M derived: sum of 2 quarters · filed 2024-04-01 | -$40.88M derived: sum of 3 quarters · filed 2024-04-01 | -$66.17M 10-K · filed 2024-04-01 |
| 2022-09-30 | -$9.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$30.02M derived: sum of 2 quarters · filed 2023-11-13 | -$55.31M 10-Q · filed 2023-11-13 | -$101.99M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$20.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$45.41M 10-Q · filed 2023-08-14 | -$92.10M derived: sum of 3 quarters · filed 2023-08-14 | -$133.61M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$25.29M 10-Q · filed 2023-05-15 | -$71.97M derived: sum of 2 quarters · filed 2023-05-15 | -$113.49M derived: sum of 3 quarters · filed 2023-05-15 | -$131.84M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$46.68M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$88.20M derived: sum of 2 quarters · filed 2023-03-30 | -$106.55M derived: sum of 3 quarters · filed 2023-03-30 | -$140.33M 10-K · filed 2023-03-30 |
| 2021-09-30 | -$41.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$59.86M derived: sum of 2 quarters · filed 2022-11-14 | -$93.65M 10-Q · filed 2022-11-14 | -$136.96M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$18.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$52.14M 10-Q · filed 2022-08-15 | -$95.45M derived: sum of 3 quarters · filed 2022-08-15 | -$136.27M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$33.79M 10-Q · filed 2022-05-10 | -$77.10M derived: sum of 2 quarters · filed 2022-05-10 | -$117.92M derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | -$43.31M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$84.14M derived: sum of 2 quarters · filed 2022-03-28 | -$92.96M 10-K · filed 2022-03-28 | |
| 2020-09-30 | -$40.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$49.65M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | -$8.82M 10-Q · filed 2021-08-12 |